



THE WHITE HOUSE
WASHINGTON

COVID-19 Press Briefing

March 23, 2022



Daily Change in COVID-19 Cases, US

January 22, 2020 – Mar 21, 2022

TOTAL Cases Reported Since 1/22/20

79,621,004

NEW Cases Reported to CDC on 3/21/22

47,454

Change in 7-Day Case Average


-9.2%

Current 7-Day Case Average (3/15/22 - 3/21/22)

28,657

Prior 7-Day Case Average (3/8/22 - 3/14/22)

31,558



New Admissions of Patients with Confirmed COVID-19, US

August 1, 2020 – Mar 20, 2022

Patients Currently Hospitalized with COVID on 3/20/22

14,123

New Admissions on 3/20/22

1,496

Peak in New Admissions (1/12/22)

22,920

Change in 7-Day Average of New Admissions


-22.8%

Current 7-Day Average of New Admissions (3/14/22 - 3/20/22)

1,925

Prior 7-Day Average of New Admissions (3/7/22 - 3/13/22)

2,494



Daily Change in COVID-19 Deaths, US

January 22, 2020 – Mar 21, 2022

TOTAL Deaths Reported Since 1/22/2020

971,422

NEW Deaths Reported to CDC on 3/21/22

911

Change in 7-Day Death Average

-26.2%

Current 7-Day Death Average (3/15/22 - 3/21/22)


862

Prior 7-Day Death Average (3/8/22 - 3/14/22)

1,167

Forecasted Total Deaths by week ending (04/09/22)

980,000 to 990,000



COVID-19 Treatment Update



Medical Management of the SARS-CoV-2-Infected Patient


■ Control of symptoms

■ End-organ support

■ Antivirals and immunomodulators



Therapeutic “Toolkit” for Non-Hospitalized Patients with COVID-19 in the Omicron Era





FDA Authorizes New Monoclonal Antibody for Treatment of COVID-19 that Retains Activity Against Omicron Variant

- **EUA issued for **bebtelovimab** for treatment of mild to moderate COVID-19 in adults and pediatric patients (≥ 12 years of age and ≥ 40 kg):**
 - **With positive results of direct SARS-CoV-2 viral testing and**
 - **Who are at high risk for progression to severe disease, and**
 - **For whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate**



Bebtelovimab Neutralization Data: Selected SARS-CoV-2 Variants

Lineage	WHO Nomenclature	Fold Reduction in Susceptibility*
B.1.1.7	Alpha	No change
B.1.351	Beta	No change
P.1	Gamma	No change
B.1.617.2/AY.3	Delta	No change
B.1.1.529/BA.1	Omicron	No change
BA.1.1	Omicron [+R346K]	No change
BA.2	Omicron [BA.2]	No change

Source: FDA EUA Fact Sheet for Bebtelovimab

*Pseudotyped Virus-Like Particle Assay
No change: <5-fold reduction in susceptibility.



Bebtelovimab Developed From Antibodies From a Recovered COVID-19 Patient

- **Bebtelovimab was developed from antibodies co-discovered by AbCellera in collaboration with the NIAID Vaccine Research Center and developed by Eli Lilly.**
- **Millions of a patient's antibody-producing cells screened to identify and isolate potent antibodies that bind to SARS-CoV-2**
 - **Platform also used in discovery of bamlanivimab (first SARS-CoV-2 monoclonal antibody to be granted EUA)**





FOR IMMEDIATE RELEASE
February 10, 2022

Secretary Becerra Announces HHS Purchase of 600,000 Treatment Courses of New Monoclonal Antibody That Works Against Omicron


- **Federal government has purchased 600,000 treatment courses of bebtelovimab (manufactured by Eli Lilly)**
- **Contract also includes a future option for 500,000 additional doses**



Will I Need a 4th COVID-19 Shot?



More Information



NIH COVID-19 Treatment Guidelines

www.covid19treatmentguidelines.nih.gov



Find COVID-19 Vaccines

Vaccines.gov

1-800-232-0233





THE WHITE HOUSE
WASHINGTON

Q&A



THE WHITE HOUSE
WASHINGTON

WH.GOV